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The study of pancreatic cancer has prompted the development of numerous mouse
models that aim to recapitulate the phenotypic and mechanistic features of this deadly
malignancy. This review accomplishes two tasks. First, it provides an overview of the
models that have been used as representations of both the neoplastic and carcinoma
phenotypes. Second, it presents new modeling schemes that ultimately will serve to
more faithfully capture the temporal and spatial progression of the human disease,
providing platforms for improved understanding of the role of non-epithelial compartments
in disease etiology as well as evaluating therapeutic approaches.
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INTRODUCTION
There has been a noticeable increase (near doubling) in the
5-year survival of pancreatic cancer patients, though the num-
ber remains quite low at about 6–7% (SEER Stat Fact Sheets:
Pancreas Cancer—NCI). Much of this stems from a few more
potent clinical therapies [folfirinox (Papadatos-Pastos et al.,
2014), nab-paclitaxol (Borazanci and Von Hoff, 2014), and var-
ious combinations with gemcitabine (Tian et al., 2013)] that
improve on previous survival rates. Thus, begins a new drive
to employ relevant preclinical models with which to test novel
drugs that can further improve patient survival. Indeed, there are
already a few mouse models that can be used, with KPC mice
(as described below) being one model that currently boasts a
strong recapitulation of the paradigm observed in human pan-
creatic adenocarcinoma. Yet, further advances on mouse models
will not only generate additional preclinical models but, perhaps
more importantly, demonstrate the utility of newer diagnostic
and/or therapeutic targets. The main objective of this review is
to highlight past and present mouse models of pancreatic can-
cer [see (Guerra and Barbacid, 2013) for a more thorough review
of current models] in order to propose continued engineering of
more relevant mouse systems. These future models could then
be employed to better understand the role of non-parenchymal
compartments during the development of disease as well as build
inducible systems that allow multiple allelic changes at various
intervals.
TRANSGENIC MODELS
Initially, development of cancer in mouse pancreas was demon-
strated by targeting Myc and TGFα to mouse pancreatic
acinar cells (EL-Myc and EL-TGFα), which demonstrated
acinar-to-ductal metaplasia leading to exocrine carcinoma with
focally distinct ductal-like lesions (Sandgren et al., 1990, 1991,
1993; Grippo and Sandgren, 2012). Previous targeting of onco-
gene expression via the elastase (EL) promoter proved effective
at inducing exocrine pancreatic neoplasms in transgenic mice,
including EL-SV40 TAg and EL-Hras (Ornitz et al., 1985, 1987;
Quaife et al., 1987). These two models developed acinar hyper-
plasia (Ornitz et al., 1987) and carcinoma (Quaife et al., 1987)
while EL-TGFαmice produced severe fibrosis, tubular complexes,
and aberrant cell morphology (Sandgren et al., 1993). Older
EL-TGFα mice eventually develop carcinoma, and tumor devel-
opment was enhanced in a p53 null background and concomitant
with partial or whole loss of INK4a or SMAD4 (Wagner et al.,
2001). The metaplasia in EL-TGFα/p53+/− mice was character-
ized along with its genomic signature (Schreiner et al., 2003)
and increased expression of Pdx1, a gene necessary for pan-
creas development and often expressed in pancreatic cancer, was
observed in mice with overexpression of TGFα (Song et al., 1999).
Additionally, the EL-KRAS model, which directs human mutant
KRAS transgene expression to pancreatic acinar cells via a rat
elastase driver, demonstrates a common pancreatic cancer histo-
type by inducing neoplastic, ductal lesions (Grippo et al., 2003),
often referred to as cystic papillary neoplasms (CPNs) similar
to human cystic neoplasms including IPMN and MCN (Hruban
et al., 2006).
CONDITIONAL MODELS
Conditional systems have become an asset to the mouse-
modeling field as they provide tissue specific targeting of genes.
One prominent targeting strategy included Pdx1 and Ptf1a
or p48-driven expression of Cre recombinase in mice with
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flanking Lox elements (floxed) that, upon Cre-mediated recom-
bination, generated a mutant Kras in the endogenous mouse
allele. These mice developed ductal lesions and mPanINs that
occasionally progressed to invasive cancer (Hingorani et al.,
2003). This model laid the foundation for the generation of
the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx1-Cre (KPC) model
which demonstrates a highly metastatic carcinoma that resembles
human disease (Hingorani et al., 2005). Models such as this one
have allowed for the characterization of biomarkers in pancreatic
cancer from disease initiation to metastasis (Mirus et al., 2014).
It is important to note that these floxed alleles can be targeted
to other cell types in the pancreas as demonstrated by expres-
sion of the LSL−KrasG12D/+ allele in Nestin positive cells leading
to mPanINs (Carriere et al., 2007) and caerulein-induced PDAC
(Carriere et al., 2011b).
Following the use of these models, other conditional targets
were generated utilizing similar technology. Since Transforming
Growth Factor β (TGFβ) signaling is commonly disrupted in
cancer (Principe et al., 2014) and highly so in pancreatic cancer
(Jones et al., 2008), LSL-KrasG12D/+;Tgfbr2flox/flox;Ptf 1aCre/+
mice were generated to simultaneously express mutant KrasG12D
and loss of the type 2 TGFβ receptor (Tgfbr2) in pancre-
atic epithelium. This model demonstrated an aggressive
form of pancreatic ductal adenocarcinoma (PDAC) and
explored the role of TGFβ signaling in the development
of the disease (Ijichi et al., 2006). As loss of downstream
TGFβ target SMAD4 is common in pancreatic cancer (Hahn
et al., 1996), LSL-KrasG12D/+;Dpc4flox/+;Pdx1-Cre and LSL-
KrasG12D/+;Dpc4flox/+;Ptf1aCre/+ were generated to conditionally
express KrasG12D in concert with Smad4/Dpc4 haploinsufficiency
in the pancreas, thereby inducing MCNs and subsequent PDAC
(Izeradjene et al., 2007). Additionally, IPMN-like lesions accom-
panied by PDAC and metastatic disease were shown with the
LSL-KrasG12D/+;Smad4flox/flox;Pdx1-Cre model (Bardeesy et al.,
2006; Kojima et al., 2007).
Considering the implications for loss/inactivation of p16Ink4a
and p19Arf in cellular transformation, a variety of models
have pursued this target in concert with pancreas-specific
mutations. An MT-TGFα;Ink4a/Arf−/− model was gener-
ated, ultimately demonstrating a serous cystadenoma (SCA)
phenotype that resembled human disease (Bardeesy et al.,
2002). Following the creation of this model, pancreas-
specific Kras targeting was coupled with a floxed Ink4a/Arf
locus. These LSL-KrasG12D;Ink4a/Arf flox/flox;Pdx1-Cre mice
presented with invasive, metastatic disease consistent with
human disease (Aguirre et al., 2003). In addition, the LSL-
KrasG12D/+;p16flox/flox;Pdx1-Cre model directed the knockout of
the p16Ink4a tumor suppressor gene in pancreatic epithelium.
These mice developed mPanINs, PDAC, and metastases (Qiu
et al., 2011). Characterization of this tumor suppressive axis also
prompted the generation of LSL-KrasG12D/+;Rbflox/flox;Pdx1-Cre
mice to assess the role of Rb inactivation and PDAC progression.
These mice exhibited accelerated mPanIN progression and rapid
PDAC development (Carriere et al., 2011a).
The activation of mutant Kras and heparin-binding epidermal
growth factor-like growth factor (HB-EGF) by the Means group
also demonstrated conditional targeting of two oncogenic events.
These mice featured rapid progression into the early stages of
pancreatic cancer (Ray et al., 2014).
The tumor stroma’s control of tumor growth was explored
by utilizing two conditional models of pancreatic cancer.
Shhflox/flox;Pdx1-Cre;LSL-KrasG12D/+;p53flox/+;Rosa26LSL−YFP (Sh
hPKCY) mice were generated to delete Sonic Hedgehog (SHH) in
the context on PDAC. Due to lack of SHH, these mice presented
with less tumor stroma yet more aggressive, proliferative tumors.
This phenotype was also shown utilizing a Smoothened inhibitor
in KPC mice. Additionally, VEGFR inhibition promoted SHH-
deficient tumor survival, demonstrating that SHH-formed
stroma limits tumor growth by restricting tumor angiogenesis.
(Rhim et al., 2014).
Additional study of the tumor stroma’s contribution to cancer
growth was explored via the generation of a mouse model that
crosses LSL-KrasG12D/+;Tgfbr2flox/flox;Ptf1aCre/+ mice to αSMA-
tk transgenic mice. Depletion of αSMA+ myofibroblasts in the
context of mPanINs or PDAC resulted in reduced survival char-
acterized by hypoxia, EMT, and cancer stem cells. In addition,
this model was characterized by the increase in regulatory T cells
infiltrating myofibroblast-depleted tumors. Similar results were
shown when the KPC model was used in cross with the αSMA-tk
transgenic (Ozdemir et al., 2014).
Both of these studies hold implications for the future of
stromal-directed therapies for the treatment of PDAC. Although
mouse models have been successful for such therapies (Olive
et al., 2009), the recapitulation of these results in clinical trials
has largely failed. Rhim and Ozdemir demonstrated that tumor
stroma provided a protective effect for the host. Therefore, tar-
geting the stroma may create a more aggressive form of PDAC.
As noted by Gore and Korc, the stroma’s capacity for both bene-
fit and damage must be further explored in mouse models before
potential therapies are reapplied in human trials (Neesse et al.,
2011; Gore and Korc, 2014). However, ablation of a subpopula-
tion of stromal cells (FAP+ cells) permitted immune control of
tumor growth and uncovered the efficacy of immunotherapeu-
tic antibodies (anti-CTLA-4 or anti-PD-L1), which resulted in
acute tumor regression (Kraman et al., 2010; Feig et al., 2013).
More recently it has been shown that VDR acts as a master
transcriptional regulator of PSCs to reprise the quiescent state,
resulting in induced stromal remodeling, increased intratumoral
gemcitabine, reduced tumor volume, and a 57% increase in sur-
vival compared to chemotherapy alone (Sherman et al., 2014).
The distinct outcome of these studies underscores the need to
better understand the role of desmoplastic stroma in pancreatic
cancer.
INDUCIBLE/CONDITIONAL MOUSE MODELING SYSTEMS OF
PANCREATIC CANCER
While the described conditional modeling systems have provided
invaluable insight into disease incidence and progression, they
do not fully capture the temporal component of human muta-
tions observed in the clinic. For instance, in systems relying on
Pdx or Ptf1 driven Cre, recombination occurs at E8.5 (Ohlsson
et al., 1993) or E9.5 (Obata et al., 2001), respectively. While
embryonic recombination often shortens the time to a cancer or
neoplastic phenotype, the effects of these mutations on pancreatic
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development are not fully understood, and do not faithfully
mimic the spontaneous mutations that occur in the fully formed
gland of an adult human patient.
In recent years, conditional and inducible systems have
prompted the unique ability to control when and where genes
are expressed. In particular, the development of CreERT tech-
nology (Feil et al., 1996, 1997) has prompted an array of tis-
sue specific, temporally-controlled targeting models. Both the
ElastaseCreERT2 (Desai et al., 2007) and the Ptf1aCre-ERTM
(Kopinke et al., 2012) systems have advanced the field of pan-
creatic cancer modeling by providing a means for inducibly
targeting pancreatic epithelium. Both of these systems feature a
Cre recombinase cassette fused to a Tamoxifen-responsive mutant
estrogen-receptor element that is driven by an acinar cell specific
promoter region. The Cre recombinase in each of these systems is
then able to activate gene expression in a loxP-mediated system.
The utility of the CreERT system was further demonstrated in
the KrasG12D;Rosa26NIC ;Pdx1-CreERT model, which temporally
controlled the expression of Notch and Kras and showed syner-
gistic effects between the two proteins with respect to mPanIN
progression (De La et al., 2008).
iKras∗ MODELS
The Pasca di Magliano group has also generated several models
that represent the full utilization of both spatial and temporal
control of gene expression. The iKras∗ model functions through
the transgenesis of three different types of mice. In these mice, the
Ptf1a allele drives Cre expression (Kawaguchi et al., 2002), which,
in turn, excises a stop cassette bound by two loxP sites. This stop
cassette functions to inhibit the reverse tetracycline transactivator
(rtTa) for an IRES-EGFP cassette at the R26 locus (Belteki et al.,
2005). Since Ptf1aCre/+ is mostly pancreas specific, the excision of
the stop cassette allows for the expression of both rtTa and EGFP
in the pancreatic epithelium beginning during embryogenesis
(Collins et al., 2012a).
Administering doxycycline to these animals leads to acti-
vation of rtTa and subsequent Kras∗ expression through a
TetO-KrasG12D transgene using rat mutant Kras (Fisher et al.,
2001). This inducible system provides a strong platform to
explore several relevant issues. First, the mutation of Kras can
be expressed in adult tissues, which is far more relevant to
PanIN progression to cancer observed in humans. In addition,
it allows for the abrogation of oncogenic Kras expression at var-
ious stages of cancer development and thus the study of the
dependence of developing lesions and cancer on mutant Kras.
Also, this system can be employed to investigate carcinogene-
sis in the context of tumor suppressor inactivation or additional
oncogene activation. iKras∗-p53+/− mice were also generated
to illustrate the development of PDAC when mutant Kras is
paired with the concurrent inactivation of this tumor suppres-
sor gene (Collins et al., 2012a). This model provides a frame-
work examining various features of oncogenic Kras in PDAC
development. Inhibition of mutant Kras expression through
doxycycline removal and subsequent reversion to a more nor-
mal phenotype supports continued efforts to target mutant
Kras as a therapeutic option and eventual translation to the
clinic.
Furthermore, the Pasca di Magliano group generated a model
that inducibly and conditionally activated Kras and a mutant
p53 allele (Collins et al., 2012b). These mice featured the
same iKras∗ system described above with an additional mutant
p53 allele preceded by a loxP-bound STOP cassette. Therefore,
the same Ptf1a-driven Cre-recombinase that activates the rtTa
for iKras∗ expression will also activate the mutant p53R172H
(p53∗) allele (Olive et al., 2004) by excising the preceding STOP
cassette. However, in these iKras∗p53∗ mice, oncogenic Kras
is not activated until doxycycline administration. This model
demonstrated a dual functionality by allowing the simultane-
ous, pancreas-specific targeting of two alleles (iKras∗ and p53∗)
and the inducible/reversible expression of oncogenicKras (Collins
et al., 2012b). Although the conditional LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx1-Cre (KPC) model (Hingorani et al., 2005) of
PDAC demonstrated a close mimicking of the human disease,
it lacked inducible control of Kras. This type of control over
mutantKras expression allowed for the study of its role in primary
and metastatic tumor maintenance when expressed concurrently
with mutant p53 (Collins et al., 2012b) and the demonstration
of mutant Kras-dependence on more aggressive and metastatic
pancreatic cancer.
LSL-Kras+/G12Vgeo ;EL-tTA/tetO-Cre MODELS
Additionally, the Barbacid group generated a model that accom-
plishes both temporal and spatial targeting of oncogenic Kras
using a different mutant variant (G12V vs. G12D). By cross-
ing a LSL-Kras+/G12Vgeo knockin strain (Guerra et al., 2003)
to EL-tTA/tetO-Cre mice, their group was able to obtain an
inducible system of endogenous KrasG12V mediated by doxycy-
cline control of Cre recombinase activity (Guerra et al., 2007).
Essentially, removing doxycycline in this tet-off system permits
an elastase-driven Cre specific to acinar and centroacinar cells of
the pancreas. The Cre changes LSL-KrasG12Vgeo into the active,
oncogenic KrasG12Vgeo by excising the loxP sites that contain a
stop cassette. The utility of this system is further advanced by the
detection of cells that ultimately end up with KrasG12V expres-
sion. A knockin of IRES-geo into the 3′ untranslated sequences of
the Kras allele allows for LacZ expression when the LSL cassette
is removed (Guerra et al., 2003). LacZ encodes β-galactosidase,
which is then detectable via histochemical staining. Initially, this
system was used to induce expression of oncogenic Kras at E16.5,
leading to the production of mPanIN lesions that could advance
in severity following caerulein administration (Guerra et al.,
2007). Surprisingly, doxycycline removal in adult stages resulted
in widespread expression of KrasG12V in adult acinar cells with no
phenotypic consequences. Interestingly, adult mice that express
KrasG12V in the acinar cell compartment develop mPanINs and
PDAC in the context of pancreatitis.
To explore the resistance of postnatal acinar cells to trans-
formation via the expression of Kras, the Barbacid group also
characterized the role of several tumor suppressors. These aci-
nar cells were resistant to transformation even in the absence
of tumor suppressors. Kras+/G12V ;p16Ink4a/p19Arf flox/flox;EL-
tTA/tetO-Cre andKras+/G12V ;Trp53flox/flox;EL-tTA/tetO-Cre mice
were generated and given doxycycline from birth until P60
(Guerra et al., 2011). Acting under the same tet-off system as
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described above, these mice, when taken off doxycycline, were
subject to expression of Cre recombinase in acinar and cen-
troacinar cells of the pancreas. However, instead of just activating
Kras, the Cre simultaneously excised the floxed p16Ink4a/p19Arf
or Trp53 alleles. These models, when combined with caerulein-
induced pancreatitis, presented an invasive, metastatic PDAC
phenotype (Guerra et al., 2011).
TVA-RCAS MODELS
Another mousemodel system that features viral delivery for even-
tual induction of gene expression or loss of cell targets demon-
strates the versatility of this field and another avenue for creating
complex inducible/conditional schemes. Varmus and colleagues
generated a model that introduced a replication-competent avian
leukosis sarcoma virus long-terminal repeat with splice accep-
tor (ALSV-A-based RCAS) vector to mice that expressed the
ALSV-A receptor, TVA, (Orsulic, 2002) under the control of the
elastase promoter (Lewis et al., 2003). This elastase-tva model
allowed somatic acinar cells of the pancreas to incorporate RCAS-
delivered genes, such as polyoma virus middle T antigen (PyMT)
(Gottlieb and Villarreal, 2001) or c-Myc, into the host cell
genome. These elastase-tva mice were crossed to Ink4a/Arf null
mice to create models characterizing the phenotype resulting
from these initiating oncogenic events (Lewis et al., 2003). They
found that PyMT and c-Myc induced different types of pancreatic
tumors, illustrating the impact of the initiating lesion on resulting
tumor pathology.
The development of this TVA-RCAS model was further
expanded with the coupling of the elastase-tva mice with Trp53
flox;Ptf1a-Cre (Jonkers et al., 2001) (Kawaguchi et al., 2002)
mice (Morton et al., 2008). In this model, delivery of the
PyMT oncogene is accompanied by the pancreas-specific dele-
tion of the tumor suppressor, Trp53. Results of this model
showed metastatic disease to the liver. In addition, the elastase-
tva;Trp53flox/flox;Ptf1aCre/+ mice were crossed to Ink4a/Arf flox/+
(Krimpenfort et al., 2001) mice to assess tumor development in
the context of a simultaneous p53 deficiency and Ink4a/Arf sin-
gle allele deletion. Results of this model elucidated a much more
aggressive tumor model after PyMT activation via virus adminis-
tration (Morton et al., 2008). This model succeeds as an example
of both conditional and temporal control of gene expression
by combining both pancreas–specific deletion of Trp53 via Cre-
recombinase activity and acinar cell-directed, inducible PyMT
expression via elastase-tva targeting.
Lewis and his group expounded upon these findings by cross-
ing the elastase-tva model with LSL-KrasG12D;Ptf1aCre/+ mice
(Hingorani et al., 2003) to assess the impact of activated Wnt sig-
naling in the context of KRAS-induced pancreatic tumorigenesis
(Sano et al., 2014). These mice were injected with chick fibrob-
lasts that produced ALSV-A-based RCAS vectors encoding Wnt1
or a GFP control, ultimately resulting in host genome uptake
of these genes in pancreatic acinar cells and their progenitors.
Thus, this model allowed for the targeting of Wnt1 to the pancre-
atic epithelium and subsequent characterization of its signaling
activity when introduced in concert with Kras activation. They
found that in this context, activated Wnt signaling induced the
formation of mucinous cystic neoplasms (MCN). Interestingly,
these mice displayed higher Wnt signaling in the stroma of the
MCNs, rather than in the cyst epithelium, which is consistent with
MCN patient data (Sano et al., 2014). These results suggest that
Wnt ligands may act in a paracrine fashion to stimulate MCN
development.
EXPLORING INDUCIBLE/CONDITIONAL SYSTEMS COUPLED
WITH EPIGENETIC EVENTS
The significance of factors external to genomic changes in these
models must not be overlooked. Multiple mutant Kras-expressing
models have demonstrated the contribution of inflammation and
dietary aspects to pancreatic cancer pathogenesis, improving our
understanding of pancreatic cancer and pancreatitis as well as
the interplay between the two. It was shown that high levels of
Ras activity in cLGL-KrasG12V ;EL-CreERT generated high levels
of fibrosis and inflammation that mimicked chronic pancreatitis.
Since elevated Ras activity is also found in PDAC, this finding pro-
vided a mechanistic link between pancreatic cancer and chronic
pancreatitis (Ji et al., 2009; Logsdon and Ji, 2009).
Other mechanisms have been explored with respect to
inflammatory insult and subsequent neoplastic and cancer-
ous phenotypes. Utilizing a breadth of models, Jack’s group
established that chronic pancreatitis may provide enough insult
for insulin-expressing endocrine cells to become susceptible to
KRAS-induced transformation (Gidekel Friedlander et al., 2009).
Logsdon and colleagues also demonstrated that with caerulein
induction of acute pancreatitis in the presence of inducible
mutant Kras (LSL-KrasG12V ;EL-CreERT) there was NF-κB medi-
ated amplification of Ras activity. These mice presented with
chronic inflammation and mPanIN lesions that subsided with
the inhibition of Cox-2 or deletion of IKK2 (Daniluk et al.,
2012). This effect was also demonstrated in KC mice with loss
of Cox-2 despite the additional loss of pTEN, highlighting the
potential role of AKT activation in chemoresistance (Hill et al.,
2012). Likewise, the LSL-KrasG12V ;EL-CreERT model was used
in a cross with Cox-2 conditional knockout mice to study the
effects of high fat diets on PDAC. LSL-KrasG12V ;EL-CreERT mice
fed high fat diet presented with increased fibrosis, mPanINs,
and PDAC compared to no increased mPanIN lesions or PDAC
in COXflox/flox;LSL-KrasG12V ;EL-CreERT mice fed the same diet
(Philip et al., 2013). Similarly, KC mice were shown to generate
mPanIN lesions at an earlier onset following a high fat, high calo-
rie diet with a subsequent increase in infiltration of macrophages
and T cells in an expanded stromal bed (Dawson et al., 2013).
Progression of mPanINs and PDAC has also been explored in
the context of inhibitors to the Ras signaling pathway. Gefitinib,
an EGFR inhibitor, was given to LSL-KrasG12D/+;Ptf1aCre/+ mice,
demonstrating a prevention of mPanIN and PDAC development
(Mohammed et al., 2010). Similarly, it was shown that inhibition
of EGFR does not allow for RAS levels sufficient for the transfor-
mation seen in PDAC (Ardito et al., 2012; Navas et al., 2012).
FUTURE APPLICATIONS OF INDUCIBLE/CONDITIONAL
MODELING SYSTEMS
The mouse-modeling field has capitalized on conditional and/or
inducible Cre-lox technology to target gene expression in numer-
ous cell types. However, the overwhelming majority of pancreatic
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cancer models rely on Cre-lox to drive oncogenic Kras in the
pancreatic epithelium, excluding the use of non-epithelial Cre
systems and limiting the ability to target other cells types involved
in carcinogenesis. Therefore, utilizing non-Cre-lox driven systems
to target mutant Kras to pancreatic epithelium will allow compat-
ibility with a vast array of preexisting Cre-lox systems that target
genetic changes to additional cell types including the stroma and
hematopoietic cell compartments.
The use of single transgenic or knockin systems in combina-
tion with Cre-lox models that target non-parenchymal cells in
the pancreas can circumvent some of the limitations that arise
when using Cre-lox to drive an initiating event like mutant Kras.
FIGURE 1 | Mimicking human tumorigenesis through temporal
modeling of pancreatic cancer. A key difference between human pancreatic
cancer and commonly used mouse models is in the timing of mutations. In
human patients, Kras mutations are often considered an initiating event,
occurring in adult cells, soon followed by mutations to p16, and later p53
and/or SMAD4. Yet in most models, Kras and altered tumor suppressor
genes are induced simultaneously in the developing embryo. Despite a
human-like histotype, these models have yet to be accurate predictors of
outcomes observed in clinical trials. Therefore, we propose that using
combinations of several systems to drive sequential Kras, p16, and
SMAD4/p53 mutations may lead to more human-like disease that responds
to therapy more like that observed in the clinic.
FIGURE 2 | Temporal modeling via two inducible systems. In order to
address the issue of successive induction of mutations as they occur in
human, several modeling systems can be employed. In this example, as
designed by the Pasca di Magliano group, expression of Cre-recombinase is
driven by the Ptf1a promoter. This is combined with a LSL cassette followed
by an rtTA sequence. In the presence of Cre, the stop codon is excised, and
rtTA is transcribed. This allows for interaction with a third transgene, a
TRE-Kras. When doxycycline is administered, oncogenic Kras expression is
induced. By activating this system at 1 month, it would allow a simulated Kras
mutation in near-adult tissues. Once lesions manifest, this can be followed by
the induction of a second transgene, a mutant p53 driven by a Sox9-FLPERT2
recombinase. This will excise a stop codon in front of a mutant p53 sequence
in the presence of tamoxifen, and drive mutant p53 expression. The p16
allele could also be engineered in the same manner. Timing of these events
will likely have to be determined empirically, as mutant Kras expression in
adult pancreas may not lead to the development of neoplastic lesions without
an external stimulus (like caerulein). Indeed, a third allelic alteration may be
necessary to drive a more aggressive metastatic phenotype (see Figure 3).
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The EL-KRAS model may be a prime candidate for combined
Cre-lox targeting of other cell types, as these mice develop acinar-
to-ductal metaplasia and cystic papillary neoplasms (CPN) that
resemble human cystic disease in the pancreas. These lesions did
progress to PDAC in a p16 null background or acinar carcinoma
when in a p53 null background (personal communication with
Dr. Eric Sandgren).
EL-TGFα (Sandgren et al., 1990) and Mist1KrasG12D/+
(Tuveson et al., 2006) models can serve as potential neoplastic
drivers used in concert with Cre-lox targeting. EL-TGFα mice
have been employed in combination with p53 loss (Greten et al.,
2001; Schreiner et al., 2003) to generate a model of advanced
pancreatic cancer with hallmark genetic features (loss of p16,
inactivation of Cdkn2a) reminiscent in human disease and, in
combination with mutant Kras, development of CPN that resem-
bles human IPMN (Siveke et al., 2007). EL-TGFα does lead to
proliferation of acinar cells and fibroblasts and focally generated
metaplastic lesions derived from acini (Sandgren et al., 1990).
Yet, there was no reported observation of neoplasia or more
advanced lesions in this model. Mist1KrasG12D/+ mice developed
a predictable lethal pancreatic cancer phenotype characterized by
acinar metaplasia and dysplasia in its early stages (Tuveson et al.,
2006). Despite being a strongmodel of the pancreatic neoplasia to
cancer paradigm as an ectopic model of mutant Kras expression,
Mist1KrasG12D/+ mice did, rather unexpectedly, develop hepato-
cellular carcinoma (Tuveson et al., 2006). This feature of the
model may be of potential concern when attempting to evalu-
ate the phenotypes of genetically engineered mice that employ
this particular initiating event. However, an inducible targeting of
LSL-KrasG12D/+ with Mist1CreERT2/+ produced mPanIN lesions,
indicating the relevance of the Mist1-expressing compartment in
the origins of PDAC (Habbe et al., 2008). Although EL-KRAS
FIGURE 3 | Temporal modeling via three inducible systems. As human
malignancies often involve several mutations, a compound inducible system
may be employed to target three successive transgenes to the same cell
type. For example, mtKras may be first induced through a TVA/RCAS virus
system. In this system, expression of a TVA receptor is targeted to the
pancreas via the elastase promoter. Upon reaching adulthood, animals can be
administered a RCAS virus coding for the mtKras gene. This will interact only
with cells expressing the TVA receptor, allowing for targeted and inducible
expression of KRAS in the pancreas. A second mutation, such as loss of p16,
can then be induced in the same cells via an elastase driven tTA that, in the
presence of doxycycline, will induce expression of Cre through TRE-Cre.
Combining this with a p16flox/flox gene will allow for doxycycline-induced loss
of the p16 gene, and the second genetic hit. Finally, a tamoxifen-responsive
Sox9-FLPERT2 can target cells expressing ductal markers (including those
having undergone acinar-ductal metaplasia), allowing for inducible expression
of mtP53 via an FSF cassette, providing the third genetic hit as it often occurs
in humans. It is important at each induction point that promoter/gene
regulatory elements employed to run the next step be evaluated in the
previous model. Hence, acinar-specific markers (eg., Amylase) should be
assessed in pancreas following mutant Kras expression (TVA/RCAS delivery)
and Sox9 antibodies should be used to demonstrate Sox9 expression in
mtKras expressing pancreas with loss of p16. This would need to be done at
the empirically derived time points (times provided in this figure are merely
considerations) when the next induction is scheduled to begin.
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mice do, on occasion, develop PanIN-like lesions, these are not
the predominant histotype in the pancreas, as PanIN lesions are
more frequently observed in human disease. Nonetheless, these
transgenic approaches are compatible with non-mutant Kras
driving Cre-lox systems and may prove useful in understanding
disease etiology in combination with genetic manipulations in
other cell compartments. Thesemodels do have utility with future
approaches, though they lack recapitulation of the predominant
clinical histotype (PanIN to PDAC).
Therefore, a FLP/FRT KRASmodel poses the most promise for
inducing Kras mutations that result in a PanIN-like phenotype
while allowing the use of Cre-lox to target different genetic events
in other cell types. In a manner similar to the Cre-lox system,
FLP/FRT utilizes a recombinase called flippase to target FLP
recombinase targets that flank an endogenous gene (Dymecki,
1996). Unlike Cre, which is derived from P1 bacteriophage,
the FLP recombinase is derived from Saccharomyces cerevisiae
(Sadowski, 1995). Ideally, a desirable model would involve the
generation of a pancreas-specific FLP directed toward a FRT tar-
get sequence that flanks a stop codon upstream of oncogenicKras.
At this point, a pancreas-specific FLP may be possible with the
intraductal injection of an adenovirus FLP or the generation of
an EL-tTA;TetO-FLP;FSF-KrasG12D/+ mouse. Ideally, this mech-
anism would drive mutant Kras in a near identical fashion as
EL-Cre;LSL-KrasG12D/+ while still allowing for the targeting of
non-epithelial cell types with Cre-lox.
While this type of model would increase our understanding
of the contributions of stromal, hematopoietic, and other cell
types to pancreatic carcinogenesis, the ultimate goal of such a
system would be the design of a layered model that is simul-
taneously and/or sequentially inducible. Mimicking a temporal
progression of gene mutations in specific cellular compartments
requires the use of multiple systems employing different modes
of induction. As described, the CreERT system has been well
established for many gene targets but alone can only deliver mul-
tiple mutations simultaneously (Frese and Tuveson, 2007). Young
and colleagues demonstrated the potential of the FLP/FRT sys-
tem when coupled with Cre-lox in lung tissue. They generated
mice with an Flp inducible allele of KrasG12D and Cre driven
mutation of the tumor suppressor, p53 (Young et al., 2011). The
FLP-FRT system, FSF-KrasG12D, was induced through an aden-
ovirus or lentivirus expressing Flpo, a version of Flp optimized
FIGURE 4 | Spatial modeling of pancreatic cancer to explore cross
compartmental interactions. Cre-loxP is the most widely used conditional
targeting system. This is also true in models of pancreatic cancer, where it is
primarily used to drive mtKRAS via a loxP-stop-loxP (LSL) cassette. However,
reliance on Cre-loxP to induce a Kras mutation limits our ability to target other
pertinent cell types in the tumor microenvironment. Should mtKras be
induced by another system, for example a Ptf1a-FLP-driven Frt-stop-Frt (FSF)
cassette, which would allow compatibility with one of the several hundred
possible Cre-loxP combinations. For instance, an αSMA-Cre to explore the
contributions of pancreas stellate cells to tumorigenesis, CD11b-Cre to target
myeloid cells, Lck-Cre to target lymphoid cells, or Cdh5-Cre to target mature
adipocytes (See Table 1).
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Table 1 | Tissue Specific Cre-lox Targeting Systems.
Compartment Cell/Tissue Type Targeting Model Reference
Epithelium Pancreatic epithelium, antral stomach, and duodenum in neonates.
Pancreatic beta islet cells in adults.
Pdx1-Cre Hingorani et al., 2003
Pancreatic acinar cells ElastaseCreERT2 Desai et al., 2007
Pancreatic acinar cells p48-Cre
Ptf1aCre/+
Ptf1aCre-ERTM
Hingorani et al., 2003; Kopinke et al., 2012
Pancreatic acinar cells Mist1Cre-ERT2/+ Tuveson et al., 2006
Mesenchyme Myofibroblast αSMA-Cre Wu et al., 2007
Myofibroblast Vim-Cre Troeger et al., 2012
Smooth muscle SMA-CreERT2 Wendling et al., 2009
Interstitial stroma of mature tissues—prostate, forestomach, skin Fsp1-Cre Bhowmick et al., 2004; Teng et al., 2011
Bone, cartilage Dermo1-Cre
Twist2-Cre
Yu et al., 2003; Chen et al., 2008; Liu
et al., 2010
Pancreatic exocrine lineages Nestin-Cre Delacour et al., 2004
Dermis, lung, pericardial connective tissue, blood vessel wall,
splenic capsule, mesangial cells of glomerulus
Col1a2-CreERT Zheng et al., 2002; Riopel et al., 2013
Nestin-negative mesenchymal progenitors Prx1-Cre Greenbaum et al., 2013
Hematopoietic CD4+ T Cells CD4-Cre Tanigaki et al., 2004
Peripheral CD8+ T Cells CD8a-Cre Maekawa et al., 2008
Liver and T lymphocytes after IFN or pI-pC induction Mx1-Cre Alonzi et al., 2001
Myeloid lineage Cd11b-Cre Boillee et al., 2006
Macrophages, granulocytes, possibly other myeloid derived cells LysM-Cre Clausen et al., 1999
T lymphocytes and thymocytes Lck-Cre Tomita et al., 2003; Choi et al., 2013
Hematopoietic cell lineages to peripheral blood, bone marrow, and
spleen [Ectopic expression in PDAC (Fernandez-Zapico et al., 2005)]
Vav1-Cre Daria et al., 2008
Neutrophils, monocytes/macrophages, some dendritic cells Lactotransferrin-Cre Kovacic et al., 2014
Hematopoietic stem cells/progeny Pf4-Cre Calaminus et al., 2012
Immature B lymphocytes CD19-Cre Zhang et al., 2012
Lymphoid and granulocyte-monocyte progenitors Flt3-Cre Buza-Vidas et al., 2011
Adipose Brown and white adipose tissue aP2-Cre
FABP4-Cre
Cole et al., 2012
Brown and white adipose tissue aP2-CreERT2 Dali-Youcef et al., 2007
Muscle, white adipose tissue, brain GLUT4-Cre Lin and Accili, 2011
Brown and white adipocytes, skeletal muscle, dermis Myf5-Cre Sanchez-Gurmaches and Guertin, 2014
Brown and white adipose tissue Adipoq-Cre Berry and Rodeheffer, 2013
Mature adipocytes Cdh5-Cre Berry and Rodeheffer, 2013
White adipocytes PdgfRα-Cre Berry and Rodeheffer, 2013
White, inguinal white, and brown adipose tissue Retn-Cre Mullican et al., 2013
for mammalian use. Utilization of this mammalian version of
Flp, as opposed to Flpe, was utilized due to its higher recom-
bination efficiency (Farley et al., 2000). Injection of the aden-
ovirus/lentivirus activates mutant Kras and results in numerous
lung tumors, ultimately confirming that FSF-KrasG12D results in
a phenotype similar to LSL-KrasG12D/+allele. This virus-driven
FLP-FRT was coupled with a tamoxifen-driven p53 mutation via
Cre recombinase activity (Young et al., 2011).
The TVA-RCAS targeting of epithelial tissue and subsequent
stromal phenotype indicates further opportunity for the utiliza-
tion of this system to target other cell types simultaneously. For
example, the conditional nature of this model would allow for the
targeting of genes to the stroma via a TVA-RCAS system utilizing
a driver such as αSMA or Vimentin. Taking this further, the pos-
sibility arises for generation of a trigenic model. Utilizing Cre-lox,
FLP/FRT, and TVA-RCAS targeting methods in the same mouse
would provide a novel way to target several different cell types in
both a conditional and inducible manner.
ADVANCING THE UTILITY OF INDUCIBLE/CONDITIONAL
MODELING
While the aforementioned models are undoubtedly technological
achievements, their ability to faithfully recapitulate human dis-
ease is still limited. Clinically, at least two gene mutations occur
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to produce PDAC. Kras is believed to be the first mutation in
a series of transformation events that lead to PDAC in adults.
Subsequent major mutations include those to p53, SMAD4, or
p16INK4a, among several others (Hezel et al., 2006). With current
mouse models, recombination events affecting Kras and these
other genes occur either during embryonic development or con-
comitantly sometime after pancreas formation, in the case of
inducible systems. However, they fail to capture the step-wise
mutation process that occurs in the adult pancreata of human
patients.
Layeringmultiple inducible systems to target the same cell type
and cause multiple mutations in a step-wise manner would assist
in capturing a more faithful representation of human disease pro-
gression (Figure 1). For example, targeting Kras with an EL-tTA
or EL-TVA system would provide a mechanism for issuing the
first hit of genetic instability in both a temporal and tissue-specific
manner. However, it should be noted that elastase targeting in
these systems may be dramatically inefficient after pancreas cells
advance to a ductal and/or abnormal phenotype. Ablation of a
second gene such as p53, SMAD4, or p16INK4a could then be
controlled by a Cre-ERT2 system directed toward the same cells
expressing mutant KRAS (Figure 2). Finally, a third system, the
FLP/FRT, could be utilized to mutate a third gene in an effort
to drive metastatic phenotypes. This trigenic model, which is
just one example of many possible inducible/conditional muta-
tion schemes, would better serve to mimic the progressive nature
of PDAC (Figure 3). However, generation of such models inher-
ently results in very complex breeding patterns. Additionally,
once these trigenic mice are established the induction of differ-
ent mutations requires a labor-intensive injection scheme and
administration of doxycycline over extended periods of time.
From a functional standpoint, the utilization of
inducible/conditional drivers other than Cre recombinase
for the activation of mutant KRAS allows for subsequent Cre-
lox targeting of cell types outside the epithelial compartment
(Figure 4). Strategically, withholding Cre-lox targeting of Kras
encourages the use of abundant, pre-existing Cre-lox systems
(Table 1) that can target stromal, hematopoietic, and adipose
compartments. However, this type of modeling is not necessarily
relevant from a clinical standpoint, due lack of evidence that
these non-epithelial mutations are common in human PDAC.
Nevertheless, this approach allows for more rigorous evaluation
of the contributions that different components of the tumor
microenvironment (TME) have on carcinogenesis. Insight into
the mechanism behind TME involvement in tumor progression
and metastatic phenotypes may provide strategies and the
rationale for targeting these compartments with certain thera-
peutic agents. These inducible/conditional systems will be highly
relevant in studying the therapeutic value of a genetic target in
mature tumors and not at the initiation stages. For instance, a
model with expression of oncogenic KrasG12V and deletion of p53
with an EL-tTA FLP system used in conjunction with ablation of
a target gene, such as EGFR, by an ubiquitous Cre-ERT2 system
is under development in the Barbacid laboratory.
The goal of such systems is to recapitulate the human con-
dition, which can only be done in part. Indeed, mouse models
are simply that—models that will never completely recapitulate
human PDAC. It is critical to generate these models in a clean
background strain to eliminate the potential causative role that
genetic variability among chimerics may play when comparing
test and control animals, particularly as the complexity of these
models increases. The layering of multiple schemes lends itself
to amplifying the anomalies produced by one model and poten-
tially augmenting those in another system as they are combined.
Despite these caveats, current and future inducible and/or con-
ditional models will lead to a more faithful representation of
human disease, which is essential to teasing out the phenotypic
and mechanistic aspects of pancreatic cancer that will ultimately
improve outcomes in the clinic.
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